Thomas Yang Sun - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Thomas Yang Sun

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Endocrine-Related Cancer|September 27, 2022

Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sitesThomas Yang Sun, Lan Zhao, Paul Van Hummelen, et al.

JTO Clinical and Research Reports|April 6, 2023

Brief Report: High Levels of CD47 Expression in Thymic Epithelial TumorsThomas Yang Sun, Brandon Nguyen, Simon B Chen, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Endocrine-Related Cancer|September 27, 2022

Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sitesThomas Yang Sun, Lan Zhao, Paul Van Hummelen, et al.

JTO Clinical and Research Reports|April 6, 2023

Brief Report: High Levels of CD47 Expression in Thymic Epithelial TumorsThomas Yang Sun, Brandon Nguyen, Simon B Chen, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.

Pageof 2